Smithkline Beecham Corporation

Shifa Biomedical Corporation

Other

Temple University

Nabil A Elshourbagy

Shaker Ahmed Mousa

Derk J Bergsma

Harold V Meyers

Usman Shabon

Sherin Salaheldin Abdel-Meguid

Paul G Lysko

Xiaotong Li

Lisa Vawter

Ping Tsui

David Michalovich

Mary E Brawner

Pamela A Lane

Robert S Ames

Mitchell Stuart Gross

Robert N Willette

Anthony J Arleth

Henry S Sarau

John Adamou

Steven M Ruben

Magid A Abou-Gharbia

Wayne Everett Childers

Benjamin E Blass

Catherine E Ellis

Henry M Sarau

Rogelio Martinez

Victor Ghidu

Randall Forrest Smith

Pankaj Agarwal

John E Adamou

Disclosed are Nanoformulated compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL- and related cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) nano-formulation of compounds and methods of using the same

Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases

Endothelial Lipase (EL) inhibitors and methods of using such inhibitors for treating conditions implicating EL are provided herein. The present invention meets the needs in the field by providing small molecule inhibitors of EL function that can be used therapeutically to raise HDL cholesterol levels in blood, and can be used in the prevention and/or treatment of cholesterol and lipoprotein metabolism disorders, including, but not limited to, familial hypercholesterolemia, atherogenic dyslipidemia, atherosclerosis, and, more generally, cardiovascular disease (CVD).

Anti-endothelial lipase compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases

Disclosed are compounds of the class of 2-phenylacetamides that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), and methods of using these modulators to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia.

Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Disclosed are compounds that modulate the physiological action of the proprotein convertase subtilisin kexin type 9 (PCSK9), as well as therapeutic methods for use of such compounds to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease (CVD), including treatment of hypercholesterolemia. Examples of compounds include thiadiazole, isoxazole, 1,2,4-triazole, thiazole, indole, pyrazole, and pyrrolinone derivatives.

AXOR34 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR34 polypeptides and polynucleotides in diagnostic assays. Further disclosed are screening assays to identify agonists and antagonists of the interaction between AXOR34 and its ligands, NmU-8, NmU-25, and NmU-23.

Molecular cloning of a 7TM receptor (AXOR34) and screening methods thereof

Molecular cloning of a 7TM receptor (AxOR34) and screening methods thereof

Urotensin-II Receptor (UTB-R) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Urotensin-II Receptor (UTB-R) polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Polynucleotides encoding mouse urotensin-II Receptor (UTB-R)

HC/BTLP polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing hC/BTLP polypeptides and polynucleotides in the design of protocols for the treatment of restenosis, atherosclerosis, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), benign prostatic hypertrophy (BPH), nephritis, fibrosis, glomerulonephritis, gliosis, cirrhosis and anomalies of wound healing, such as keloids among others, and diagnostic assays for such conditions.

Human cardiac/brain tolloid-like protein

AXOR10 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing AXOR10 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Axor10, a g-protein coupled receptor

Human G-Protein Coupled Receptor HNFDS78 polypeptides and DNA (RNA) encoding such G-Protein Coupled Receptor HNFDS78 and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such G-Protein Coupled Receptor HNFDS78 for the treatment of diseases, such as, atherosclerosis, inflammatory disease, and infectious disease. Antagonists against such G-Protein Coupled Receptor HNFDS78 and their use as a therapeutic to treat disease are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding G-protein coupled receptors and for detecting altered levels of the polypeptide in a host.

Nucleic acids encoding the G-protein coupled receptor HNFDS78

Human Marco scavenger receptor polypeptides (HMarcoSR) and DNA (RNA) encoding such HMarcoSR and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such HMarcoSR for the treatment of various cardivascular disorders, gangrene, and loss of function in the extremeties. Antagonists against such HMarcoSR and their use as a therapeutic to treat of various cardivascular disorders, gangrene, and loss of function in the extremeties are also disclosed. Also disclosed are diagnostic assays for detecting diseases related to mutations in the nucleic acid sequences and altered concentrations of the polypeptides. Also disclosed are diagnostic assays for detecting mutations in the polynucleotides encoding the HMarcoSR and for detecting altered levels of the polypeptide in a host.

Human marco scavenger receptor

The mouse GPR43 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing mouse GPR43 polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Polynucleotide encoding a Mouse 7-transmembrane GPR43 receptor

Novel 7TM receptor (H2CAA71) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing Novel 7TM receptor (H2CAA71) polypeptides and polynucleotides in the design of protocols for the treatment of infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; anorexia; bulimia; asthma; Parkinson's disease; acute heart failure; hypotension; hypertension; urinary retention; osteoporosis; angina pectoris; myocardial infarction; ulcers; asthma; allergies; benign prostatic hypertrophy; and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, severe mental retardation and dyskinesias, such as Huntington's disease or Gilles dela Tourett's syndrome, among others and diagnostic assays for such conditions.

Growing community of inventors

West Chester, PA, United States of America

Nabil A Elshourbagy